α-synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model

Journal of Neuropathology and Experimental Neurology

Volumn 72, Issue 7, 2013, Pages 624-645

  Sanchez Guajardo, Vanesa ^a   Annibali, Ambra ^a   Jensen, Poul Henning ^a   Romero Ramos, Marina ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

CD4 cells; Foxp3; GDNF; Major histocompatibility complex molecules; Microglia; Parkinson disease; Vaccination

Indexed keywords

ALPHA SYNUCLEIN; CD4 ANTIGEN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN G; RECOMBINANT ALPHA SYNUCLEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; FEMALE; GENE OVEREXPRESSION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROGLIA; NEURITE; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; STEREOTACTIC TREATMENT; SUBSTANTIA NIGRA; VACCINATION; VIRAL GENE DELIVERY SYSTEM;

ALPHA-SYNUCLEIN; ANIMALS; ANTIGENS, CD; CELL COUNT; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITOPE MAPPING; FEMALE; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INCLUSION BODIES; MICROGLIA; MOTOR ACTIVITY; NERVE FIBERS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; VACCINATION;

EID: 84879934105     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31829768d2     Document Type: Article

References (85)

1. Halliday GM, Stevens CH. Glia: Initiators and progressors of pathology in Parkinson's disease. Mov Disord 2011;26:6-17
2. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010;37:510-18
3. Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009;119:182-92
4. McGeer PL, Itagaki S, Boyes BE, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-91
5. Orr CF, Rowe DB, Mizuno Y, et al. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005;128:2665-74 (Pubitemid 41552950)
6. Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A metaanalysis of genome-wide association studies. Lancet 2011;377:641-49
7. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010;42:781-85
8. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18: 106Y8
9. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-47 (Pubitemid 27443610)
10. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004;55:174-79 (Pubitemid 38166993)
11. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841 (Pubitemid 37339619)
12. Spillantini MG, Crowther RA, Jakes R, et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-73 (Pubitemid 28249037)
13. Croisier E, Moran LB, Dexter DT, et al. Microglial inflammation in the parkinsonian substantia nigra: Relationship to alpha-synuclein deposition. J Neuroinflammation 2005;2:14
14. Su X, Federoff HJ, Maguire-Zeiss KA. Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res 2009;16:238-54
15. Austin SA, Floden AM, Murphy EJ, et al. Alpha-synuclein expression modulates microglial activation phenotype. J Neurosci 2006;26:10558-63 (Pubitemid 44564607)
16. Gao HM, Kotzbauer PT, Uryu K, et al. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008;28:7687-98
17. Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: A process leading to disease progression in Parkinson's disease. Faseb J 2005;19:533-42 (Pubitemid 40471244)
18. Kreutzberg GW. Microglia: A sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-18 (Pubitemid 26349059)
19. Kim SU, de Vellis J. Microglia in health and disease. J Neurosci Res 2005;81:302-13 (Pubitemid 41359284)
20. Schell H, Hasegawa T, Neumann M, et al. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience 2009;160:796-804
21. Gomez-Isla T, Irizarry MC, Mariash A, et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 2003;24:245-58 (Pubitemid 36005405)
22. Neumann M, Kahle PJ, Giasson BI, et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 2002;110:1429-39 (Pubitemid 35396914)
23. van der Putten H, Wiederhold KH, Probst A, et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000;20:6021-29 (Pubitemid 30658395)
24. Chung CY, Koprich JB, Siddiqi H, et al. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 2009;29:3365-73
25. Theodore S, Cao S, McLean PJ, et al. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 2008;67:1149-58
26. Kim S, Cho SH, Kim KY, et al. Alpha-synuclein induces migration of BV-2 microglial cells by up-regulation of CD44 and MT1-MMP. J Neurochem 2009;109:1483-96
27. Sanchez-Guajardo V, Febbraro F, Kirik D, et al. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS ONE 2010;5:e8784
28. Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E, et al. Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: Differences between wild-type and Parkinson's disease-linked mutants. PLoS ONE 2010;5:e13481
29. Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005;46: 857Y68
30. Benner EJ, Banerjee R, Reynolds AD, et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE 2008;3:e1376
31. Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002;22:2780-91 (Pubitemid 37465827)
32. Xu L, Daly T, Gao C, et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Human Gene Ther 2001;12: 563Y73
33. Kirik D, Annett LE, Burger C, et al. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: A new primate model of Parkinson's disease. Proc Natl Acad Sci USA 2003; 100:2884-89 (Pubitemid 36297593)
34. Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999;6:973-85 (Pubitemid 29295202)
35. Stoltz S, Humm JL, Schallert T. Cortical injury impairs contralateral forelimb immobility during swimming: A simple test for loss of inhibitory motor control. Behav Brain Res 1999;106:127-32 (Pubitemid 29528493)
36. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970;24:485-93
37. Paleologou KE, Kragh CL, Mann DM, et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009;132:1093-101
38. Lindersson E, Lundvig D, Petersen C, et al. p25alpha Stimulates alphasynuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J Biol Chem 2005;280:5703-15 (Pubitemid 40280050)
39. West MJ. Stereological methods for estimating the total number of neurons and synapses: Issues of precision and bias. Trends Neurosci 1999; 22:51-61 (Pubitemid 29125550)
40. Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987;147:229-63
41. Armentero MT, Levandis G, Nappi G, et al. Peripheral inflammation and neuroprotection: Systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiol Dis 2006;24:492-505 (Pubitemid 44724942)
42. Yong J, Lacan G, Dang H, et al. BCG vaccineYinduced neuroprotection in a mouse model of Parkinson's disease. PLoS ONE 2011;6:e16610
43. Barkholt P, Sanchez-Guajardo V, Kirik D, et al. Long-term polarization of microglia upon alpha-synuclein overexpression in nonhuman primates. Neuroscience 2012;208:85-96
44. Wong M, Fish EN. RANTES and MIP-1alpha activate stats in T cells. J Biological Chem 1998;273:309-14 (Pubitemid 28042210)
45. Ueda A, Zhou L, Stein PL. Fyn promotes Th17 differentiation by regulating the kinetics of RORgammat and Foxp3 expression. J Immunol 2012;188:5247-56
46. Appay V, Rowland-Jones SL. RANTES: A versatile and controversial chemokine. Trends Immunol 2001;22:83-87 (Pubitemid 32667526)
47. Lorenzl S, Albers DS, Narr S, et al. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol 2002;178: 13Y20
48. Lee EJ, Woo MS, Moon PG, et al. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 2010;185: 615Y23
49. Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2004;101:9435-40 (Pubitemid 38812892)
50. Reynolds AD, Stone DK, Mosley RL, et al. Nitrated {alpha}-synucleinY induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol 2009;182:4137-49
51. Ha D, Stone DK, Mosley RL, et al. Immunization strategies for Parkinson's disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S218Y21
52. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62. (Pubitemid 38680433)
53. Reynolds AD, Banerjee R, Liu J, et al. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol 2007;82:1083-94 (Pubitemid 350133504)
54. Reynolds AD, Stone DK, Hutter JA, et al. Regulatory T cells attenuate Th17 cellYmediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 2010;184:2261-71
55. Tran DQ, Glass DD, Uzel G, et al. Analysis of adhesion molecules, target cells, and role of IL-2 in human FOXP3+ regulatory T cell suppressor function. J Immunol 2009;182:2929-38
56. Tadokoro CE, Shakhar G, Shen S, et al. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med 2006;203:505-11
57. Tiemessen MM, Jagger AL, Evans HG, et al. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 2007;104:19446-51
58. Savage ND, de Boer T, Walburg KV, et al. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J Immunol 2008;181: 2220Y26
59. Denning TL, Wang YC, Patel SR, et al. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17Yproducing T cell responses. Nat Immunol 2007;8:1086-94 (Pubitemid 47423756)
60. Carson MJ, Sutcliffe JG, Campbell IL. Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation. J Neurosci Res 1999;55:127-34 (Pubitemid 29014418)
61. Yamazaki S, Steinman RM. Dendritic cells as controllers of antigenspecific Foxp3+ regulatory T cells. J Dermatol Sci 2009;54:69-75
62. O'Connor RA, Anderton SM. Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease. J Neuroimmunol 2008;1931:1-11
63. Chiu IM, Chen A, Zheng Y, et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci USA 2008;105:17913-18
64. Liang B, Workman C, Lee J, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008;180:5916-26
65. Shevach EM. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity 2009;30:636-45
66. Sarris M, Andersen KG, Randow F, et al. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008;28:402-13
67. Almolda B, Costa M, Montoya M, et al. CD4 microglial expression correlates with spontaneous clinical improvement in the acute Lewis rat EAE model. J Neuroimmunol 2009;209:65-80
68. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: Too much or too little? Neuron 2009;64:110-22
69. Bessis A, Bechade C, Bernard D, et al. Microglial control of neuronal death and synaptic properties. Glia 2007;55:233-38 (Pubitemid 46225955)
70. Biber K, Neumann H, Inoue K, et al. Neuronal "on" and "off " signals control microglia. Trends Neurosci 2007;30:596-602
71. Biber K, Vinet J, Boddeke HW. Neuron-microglia signaling: Chemokines as versatile messengers. J Neuroimmunol 2008;198:69-74
72. Lindvall O, Wahlberg LU. Encapsulated cell biodelivery of GDNF: A novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp Neurol 2008;209:82-88
73. Rocha SM, Cristovao AC, Campos FL, et al. Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Neurobiol Dis 2012;47: 407Y15
74. Decressac M, Ulusoy A, Mattsson B, et al. GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease. Brain 2011;134:2302-11
75. Lo Bianco C, Deglon N, Pralong W, et al. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol Dis 2004;17:283-89 (Pubitemid 39345783)
76. Fellner L, Irschick R, Schanda K, et al. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 2013; 61:349-60
77. Zhang W, Dallas S, Zhang D, et al. Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 2007;55:1178-88 (Pubitemid 47204209)
78. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308:1314-18 (Pubitemid 40746128)
79. Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 2011;6:e19338
80. Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012;32:13454-69
81. Cao S, Standaert DG, Harms AS. The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced proinflammatory signaling in microglia. Journal of neuroinflammation 2012;9:259
82. Hunot S, Dugas N, Faucheux B, et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neuroscience 1999;19:3440-47 (Pubitemid 29203124)
83. Wang R, Han G, Wang J, et al. The role of STAT3 in antigen-IgG inducing regulatory CD4(+)Foxp3(+)T cells. Cell Immunol 2007;246: 103Y9
84. Munz C. Antigen processing for MHC class II presentation via autophagy. Front Immunol 2012;3:9
85. Appel SH, Beers DR, Henkel JS. T cellYmicroglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: Are we listening? Trends Immunol 2010;31:7-17